Melissa.Moore
@mooreorless62
Followers
2K
Following
10
Media
2
Statuses
38
CSO, Moderna Therapeutics, RNA expert
Cambridge, MA
Joined October 2008
This chief scientific officer at Moderna breaks down the misunderstandings about the mRNA in the COVID-19 vaccine, and explains how it could change the world (via @TEDTalks)
15
28
70
Today we welcome world leaders in #RNA research and therapeutics to our SAB. We will work with them to harness the power of #tRNA biology to advance a single medicine with the potential to treat thousands of diseases. Release: https://t.co/rd2XfXMGMD
https://t.co/kMConnQy7w
0
5
21
I’m very excited to be part of this new company!
We are Alltrna, the world’s first #tRNA platform company. We are harnessing the power of #tRNAbiology to create a new class of #programmablemedicines with the potential to treat thousands of diseases. https://t.co/GlrfN3gy0H
@FlagshipPioneer #tRNAtherapeutics #machinelearning
6
23
185
The pace of progress in medicine is moving at record speed. Discover how Nasdaq-100 listed Moderna is accelerating innovation to meet unmet medical needs.
0
1
5
Apparently I’ve been referenced on @nbcsnl by @MayaRudolph? I just woke up to a ton of text messages
21
162
1K
We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study. Read more: https://t.co/vYWEy8CKCv
226
2K
6K
We just announced a longer shelf life at refrigerated temperatures for mRNA-1273, our COVID-19 vaccine candidate. Read more: https://t.co/4ymyQ2NS1N
60
476
2K
Announcing the exciting PROGRAM of the 8th International #mRNA Health Conference! Comprehensive topics will be presented including a special focus on #COVID19 #vaccines! https://t.co/eYv1qfa6yk
0
5
16
Forward-Looking Information and Factors That May Affect Future Results
businesswire.com
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), ...
0
4
15
Congratulations @Alnylam! A great day for the entire RNA therapeutics community!
Today’s @US_FDA approval of GIVLAARI is a defining moment for @Alnylam as we become a multi-product commercial company, for the field of #RNAi with the 1st ever approved GalNAc-conjugate RNAi tx & most importantly, for #raredisease patients awaiting a new treatment option.
0
11
56
Thank you IUBMB!
Congratulations to Melissa Moore, Moderna Therapeutics @moderna_tx, for being named IUBMB Jubilee Lecturer at the RNA Society 2020 meeting in beautiful Vancouver, Canada. This award recognizes her outstanding contributions to RNA biology and therapeutics. @RNASociety @CSMB_SCBM
3
7
55
0
14
70
The perfect wine for a spliceosome enthusiast on #RNADay! Thanks @sainiharleen! Or should I say Dr. Saini?
5
8
70
Moderna Announces an Array of Clinical Advances and Outlines 2018 Priorities; 19 Development Candidates, including 10 Clinical Programs, Highlight Productivity of mRNA Platform https://t.co/TcoZhQjjwg
0
1
1
Moderna #JPM18 450m$ invested in R&D in 2017... pipeline below: 19 candidates, 10 clinical trials
1
4
6
Moderna to start phase II trial of @AstraZeneca-partnered VEGF project “in matter of weeks”, says Stephane Bancel #JPM18
0
1
3
Standing room only for Moderna’s presentation #JPM18
0
2
5